Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nanoform FinlandSTU:4YL +0.93%67 Days Inventory is 329.24 as of Mar. 2026, which is 237% above its 10-year median of 97.80. GuruFocus rates STU:4YL with a GF Score™ of 67/100 and a GF Value™ of €1.77 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 638 Biotechnology companies, Nanoform Finland ranks worse than 54.86% on this metric.
The historical rank and industry rank for Nanoform Finland's Days Inventory or its related term are showing as below:
STU:4YL'
s Days Inventory Range Over the Past 10 Years
Min: 6.44 Med: 97.8 Max: 201.71
Current: 201.71
During the past 10 years, Nanoform Finland's highest Days Inventory was 201.71. The lowest was 6.44. And the median was 97.80.
STU:4YL's Days Inventory is ranked worse than 54.86% of 638
companies
in the Biotechnology industry
Industry Median: 183.195
vs STU:4YL: 201.71
Nanoform Finland's Days Inventory
increased
from Mar. 2025 (118.80) to Mar. 2026 (329.24).
It might indicate that Nanoform Finland's sales slowed down.
Warning Sign:
If a company builds up inventory, it may mean it is having difficulties selling its goods.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Nanoform Finland's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.28.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Nanoform Finland's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.21.
Nanoform Finland (STU:4YL) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Nanoform Finland's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Nanoform Finland's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Nanoform Finland Days Inventory Related Terms
Nanoform Finland Days Inventory Historical Data
* Premium members only.
The historical data trend for Nanoform Finland's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:4YL vs VRTX, REGN, ALNY: Days Inventory Comparison
For the Biotechnology subindustry, Nanoform Finland's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nanoform Finland Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nanoform Finland's Days Inventory distribution charts can be found below:
* The bar in red indicates where Nanoform Finland's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nanoform Finland (STU:4YL) has a Days Inventory of 329.24 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Nanoform Finland and its competitors. This is 237% above median its historical median of 97.80. Over the past decade, Nanoform Finland's Days Inventory has ranged from 6.44 to 201.71. According to the industry distribution chart, Nanoform Finland ranks #350 out of 638 companies in the Biotechnology industry, placing it in the top 54.9%.
Is Nanoform Finland's Days Inventory too high?
Nanoform Finland's current Days Inventory of 329.24 is 237% above median its 10-year median of 97.80. Over the past 10 years, this metric has ranged from a low of 6.44 to a high of 201.71. The Biotechnology industry median Days Inventory is 183.20. Nanoform Finland's value of 329.24 is 79.7% above this industry median. Based on the distribution chart, Nanoform Finland ranks #350 out of 638 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Nanoform Finland has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nanoform Finland's Days Inventory compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nanoform Finland ranks #350 out of 638 companies for Days Inventory. This places Nanoform Finland in the lower half of its industry. The industry median Days Inventory is 183.20. Nanoform Finland's value of 329.24 is 79.7% above this benchmark. Historically, Nanoform Finland's own Days Inventory has ranged from 6.44 to 201.71 over the past decade. While the company's 10-year median is 97.80 vs. the industry median of 183.20, Nanoform Finland has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 183.20, based on 638 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nanoform Finland's current Days Inventory of 329.24 is 79.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Nanoform Finland and its competitors. For the Biotechnology industry, the median Days Inventory is 183.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nanoform Finland's current Days Inventory is 329.24, which is 237% above median its own 10-year median of 97.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanoform Finland stock overvalued right now?
Based on GuruFocus' analysis, Nanoform Finland (STU:4YL) is currently considered Possible Value Trap. The stock's GF Value™ is €1.77, compared to a current price of €0.76 — trading 57.3% below its estimated fair value. The current Days Inventory is 329.24, which is 237% above median its 10-year median of 97.80 and 79.7% above the Biotechnology industry median of 183.20. Nanoform Finland's overall GF Score™ is 67/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Nanoform Finland (STU:4YL), the current Days Inventory is 329.24 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nanoform Finland (STU:4YL) Overvalued in 2026?
Based on GuruFocus' analysis, Nanoform Finland stock appears to be undervalued.
The current stock price of €0.76 is trading 57.3% below its estimated GF Value™ of €1.77.
GuruFocus considers Nanoform Finland to be Possible Value Trap.
Key valuation signals for STU:4YL:
Days Inventory: 329.24 (237% above median its 10-year median of 97.80)
GF Value™: €1.77 vs. price of €0.76 (57.3% below fair value)
Industry Position: 79.7% above the Biotechnology median (#350 of 638)
No single metric tells the full story. See the STU:4YL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nanoform Finland PLC is a nanoparticle medicine-enabling company. The company works together with pharma and biotech partners to reduce attrition in clinical trials and enhance their molecules' formulation performance through its nano-forming services. Its patented and scalable Controlled Expansion of Supercritical Solutions (CESS) technology produces nano-formed API particles as small as 10nm. This enables poorly soluble molecules in the pharmaceutical pipeline to progress into clinical development by increasing their rate of dissolution and improving their bioavailability. Its technology provides novel opportunities in many value-enhancing drug delivery applications. Geographically, the company generates maximum revenue from Europe, followed by the United States and other regions.
67GF Score
Get the complete analysis for STU:4YL
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:4YL has been successfully added to your 
